ArticleOncotarget2017

NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.

Michael K Kießling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.